Immunochemical Characterization of Two Activator Proteins Stimulating Enzymic Sphingomyelin Degradation in vitro Absence of One of them in a Human Gaucher Disease Variant
The DOI matches its Crossref record.
Abstract
Two nonenzymic activator proteins shown previously to strongly stimulate enzymic sphingomyelin degradation in vitro were purified from human Gaucher type 1 and control spleen. Activator A1 (molecular mass 6,500 Da) had affinity for ConA-Sepharose, while activator A2 (molecular mass 3,500 Da) did not. Monospecific antibodies to each activator protein were prepared in rabbits by immunization with protein purified from type 1 Gaucher spleen. A1 and A2 activators from Gaucher type 1 spleen were shown to be immunochemically identical to A1 and A2 activators from control spleen. However, A1 and A2 activators, whether isolated from Gaucher type 1 or control spleen, were shown to be distinct proteins. Immunochemical examination of all collected fractions during the purification revealed the existence of a third activator (molecular mass 6,000 Da), which was antigenically identical to A1 activator but had no affinity for ConA-Sepharose. The two forms of A1 activator showed similar mobility on immunoelectrophoresis differing from that of A2 activator. Fibroblast extracts from controls and patients with different variants of Gaucher disease were investigated using immunodiffusion against antisera to A1 or A2 activator. In contrast to normal and Gaucher (types 1, 2 and 3) cell extracts, those of a Gaucher patient with normal glucosylceramidase activity had no visible precipitin line towards the antiserum against the two forms of A1 activator. The lack of crossreacting material to antibodies against A1 activator was confirmed by radial immunodiffusion and rocket immunoelectrophoresis. A1 activator stimulated the basal glucosylceramidase activity 5-6 fold in fibroblasts from this patient, whereas the normal effect was only a 1.2-1.5-fold stimulation. The immunological results together with the biochemical data provide evidence for the lack of an activator protein in a variant form of human Gaucher disease for the first time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kolter, T., & Sandhoff, K. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.122303.120013 · Cited by 464
“F or p er so na l u se o nl y. ANRV255-CB21-04 ARI 9 September 2005 13:22 to an abnormal juvenile form of Gaucher disease and an accumulation of glucosylceramide (Christomanou et al. 1986, Schnabel et al. 1991).”
BackgroundSphingolipid metabolism diseases
Kolter, T., & Sandhoff, K. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.05.027 · Cited by 367
Saposins: structure, function, distribution, and molecular genetics.
Kishimoto, Y., Hiraiwa, M., & O'Brien, J. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40540-1 · Cited by 328
Sphingomyelin and derivatives as cellular signals
Kolesnick, R. N. (1991) · Progress in Lipid Research · doi:10.1016/0163-7827(91)90005-p · Cited by 279
Lysosomal degradation of membrane lipids
Kolter, T., & Sandhoff, K. (2010) · FEBS Letters · doi:10.1016/j.febslet.2009.10.021 · Cited by 275
Activator proteins and topology of lysosomal sphingolipid catabolism
Fürst, W., & Sandhoff, K. (1992) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(92)90210-m · Cited by 267
Diaz-Font, A., Cormand, B., Santamaria, R., Vilageliu, L., Grinberg, D., & Chabás, A. (2005) · Human Genetics · doi:10.1007/s00439-005-1288-x · Cited by 48
Sun, Y., Liou, B., Chu, Z., Fannin, V., Blackwood, R., Peng, Y., Grabowski, G. A., Davis, H. W., & Qi, X. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102735 · Cited by 39
Metadata
- Authors
- CHRISTOMANOU, H., AIGNESBERGER, A., & LINKE, R. P.
- Venue
- Biological Chemistry Hoppe-Seyler
- Publisher
- Walter de Gruyter GmbH
- Published
- 1986-01
- Volume
- 367
- Issue
- 2
- Pages
- 879-890
- ISSN
- 0177-3593 (ISSN-L)
- OpenAlex
- W2323372801
- Cited by
- 155
- References
- 0
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.